PMID

Data

Article Title

Organization

Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.

Smithkline Beecham Pharmaceuticals

Conformationally restricted polysubstituted biphenyl derivatives with angiotensin II receptors antagonist properties.

Searle R & D And Mcr

Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.

E. I. Du Pont De Nemours

Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype.

Warner-Lambert

Nonpeptide angiotensin II receptor antagonists: N-[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives.

E. I. Du Pont De Nemours And

The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.

E. I. Du Pont De Nemours

Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8.

Washington State University

Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.

Wroclaw University Of Economics

Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.

Uppsala University

Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.

Neogenesis

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Dupont Pharmaceuticals

 

L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitor

TBA

 

1,4-substituted indoles: a potent and selective class of angiostensin II receptor antagonists

TBA

 

The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT₁ and AT₂ receptor antagonists

TBA

 

L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT₁ and AT₂ receptor subtypes

TBA

 

4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT₁ antagonists with improved affinity for the AT₂ receptor

TBA

 

α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT₁/AT₂ receptor subtype affinity (Part II)

TBA

 

2,3,6-Substituted quinazolinones as angiotensin II receptor antagonists

TBA

 

Substituted 1,3-benzodioxole & 1,3-benzodithiole -2- carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II AT₁ receptor

TBA

 

Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT₁ and AT₂ subtypes

TBA

 

Development of angiotensin II antagonists with equipotent affinity for human AT₁ and AT₂ receptor subtypes.

TBA

 

Balanced angiotensin II receptor antagonists. I. The effects of biphenyl “ortho”-substitution on AT₁/AT₂ affinities

TBA

 

Synthesis and biological evaluation of the potent isoxazolidinyl angiotensin II receptor antagonist CL332,877 and its enantiomers.

TBA

 

6-isoxazolinyl and isoxazolidinyl substituted quinazolinones as angiotensin II receptor antagonists

TBA

 

A new class of balanced AT₁/AT₂ angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities

TBA

 

Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonists

TBA

 

Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements

TBA

 

Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists

TBA

 

Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT₁ and AT₂ receptors

TBA

 

Imidazo[4,5-b]pyridine-based AT₁ / AT₂ angiotensin II receptor antagonists

TBA

 

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide

TBA

 

Angiotensin II receptor antagonists containing a phenylpyridine element.

TBA

 

Synthesis and structure-activity relationships of a novel series of non-peptide AT₂-selective angiotensin II receptor antagonists

TBA

Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.

Uppsala University

Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.

Searle

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.

Merck Research Laboratories

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

Merck Research Laboratories

A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.

Dupont Pharmaceuticals

(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.

Merck Research Laboratories

A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.

Merck Research Laboratories

Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.

E. Merck

Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.

Merck Research Laboratories

Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.

Carpibem

A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.

Merck Research Laboratories

Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.

Merck Research Laboratories

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.

Dupont Pharmaceuticals

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.

Merck Research Laboratories

1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.

Smithkline Beecham Pharmaceuticals

Imidazole-5-acrylic acids: potent nonpeptide angiotensin II receptor antagonists designed using a novel peptide pharmacophore model.

Smithkline Beecham Pharmaceuticals

Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.

Yogi Vemana University

2,3-Dihydroquinazolin-4(1H)-one derivatives as potential non-peptidyl inhibitors of cathepsins B and H.

Kurukshetra University